XML 34 R24.htm IDEA: XBRL DOCUMENT
v3.25.1

Collaboration, License, and Other Agreements (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Revenue from Contract with Customer [Abstract] |
Schedule of Collaborative Revenue | Net product sales consist of the following:
|  |  | Three Months Ended March 31,
(In millions) |  |  | 2025 |  | 2024
EYLEA HD® | U.S. |  | $ | 306.8 |  |  | $ | 200.0 |
EYLEA® | U.S. |  | 736.0 |  |  | 1,201.6 |
Total EYLEA HD and EYLEA | U.S. |  | 1,042.8 |  |  | 1,401.6 |
Libtayo® | U.S. |  | 192.5 |  |  | 159.2 |
Libtayo | Rest of world |  | 92.6 |  |  | 104.7 |
Total Libtayo | Global |  | 285.1 |  |  | 263.9 |
Praluent® | U.S. |  | 56.8 |  |  | 70.0 |
Evkeeza® | U.S. |  | 30.9 |  |  | 24.8 |
Inmazeb® | Rest of world |  | — |  |  | 1.0 |
|  |  | $ | 1,415.6 |  |  | $ | 1,761.3 |
Amounts recognized in the Company's Statements of Operations in connection with its Sanofi collaboration are as follows:
|  | Statement of Operations Classification |  | Three Months Ended March 31,
(In millions) |  |  | 2025 |  | 2024
Regeneron's share of profits |  | Collaboration revenue |  | $ | 1,018.2 |  |  | $ | 804.0 |
Reimbursement for manufacturing of commercial supplies |  | Collaboration revenue |  | $ | 165.0 |  |  | $ | 105.8 |
Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses |  | (R&D expense) |  | $ | (15.5) |  |  | $ | (18.6) |
Reimbursement of commercialization-related expenses |  | Reduction of SG&A expense |  | $ | 159.2 |  |  | $ | 139.5 |
Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:
|  | Statement of Operations Classification |  | Three Months Ended March 31,
(In millions) |  |  | 2025 |  | 2024
Regeneron's share of profits |  | Collaboration revenue |  | $ | 317.3 |  |  | $ | 333.9 |
Reimbursement for manufacturing of commercial supplies |  | Collaboration revenue |  | $ | 26.6 |  |  | $ | 22.1 |
Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses |  | (R&D expense) |  | $ | (9.4) |  |  | $ | (8.7) |
Schedule of Accounts Receivable and Deferred Revenue Information | The following table summarizes contract balances in connection with the Company's Sanofi collaboration:
|  | March 31, |  | December 31,
(In millions) |  | 2025 |  | 2024
Accounts receivable, net |  | $ | 1,192.8 |  |  | $ | 1,216.2 |
Deferred revenue |  | $ | 549.5 |  |  | $ | 571.7 |
The following table summarizes contract balances in connection with the Company's Bayer collaboration:
|  | March 31, |  | December 31,
(In millions) |  | 2025 |  | 2024
Accounts receivable, net |  | $ | 373.2 |  |  | $ | 349.9 |
Deferred revenue |  | $ | 260.0 |  |  | $ | 216.3 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration